These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome. Stagni F; Magistretti J; Guidi S; Ciani E; Mangano C; Calzà L; Bartesaghi R PLoS One; 2013; 8(4):e61689. PubMed ID: 23620781 [TBL] [Abstract][Full Text] [Related]
3. Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome. Roncacé V; Burattini C; Stagni F; Guidi S; Giacomini A; Emili M; Aicardi G; Bartesaghi R Neurobiol Dis; 2017 Oct; 106():89-100. PubMed ID: 28651891 [TBL] [Abstract][Full Text] [Related]
4. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome. Begenisic T; Baroncelli L; Sansevero G; Milanese M; Bonifacino T; Bonanno G; Cioni G; Maffei L; Sale A Neurobiol Dis; 2014 Mar; 63():12-9. PubMed ID: 24269730 [TBL] [Abstract][Full Text] [Related]
5. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Guidi S; Stagni F; Bianchi P; Ciani E; Ragazzi E; Trazzi S; Grossi G; Mangano C; Calzà L; Bartesaghi R Brain Pathol; 2013 Mar; 23(2):129-43. PubMed ID: 22817700 [TBL] [Abstract][Full Text] [Related]
6. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313 [TBL] [Abstract][Full Text] [Related]
7. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735 [TBL] [Abstract][Full Text] [Related]
8. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome. Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823 [TBL] [Abstract][Full Text] [Related]
9. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes. Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991 [TBL] [Abstract][Full Text] [Related]
10. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts. Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335 [TBL] [Abstract][Full Text] [Related]
11. Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome. Nosheny RL; Belichenko PV; Busse BL; Weissmiller AM; Dang V; Das D; Fahimi A; Salehi A; Smith SJ; Mobley WC Neurobiol Dis; 2015 May; 77():173-90. PubMed ID: 25753471 [TBL] [Abstract][Full Text] [Related]
12. Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome. Ahmed MM; Dhanasekaran AR; Block A; Tong S; Costa AC; Stasko M; Gardiner KJ PLoS One; 2015; 10(3):e0119491. PubMed ID: 25793384 [TBL] [Abstract][Full Text] [Related]
13. Normal protein composition of synapses in Ts65Dn mice: a mouse model of Down syndrome. Fernandez F; Trinidad JC; Blank M; Feng DD; Burlingame AL; Garner CC J Neurochem; 2009 Jul; 110(1):157-69. PubMed ID: 19453946 [TBL] [Abstract][Full Text] [Related]
14. Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome. Billingsley CN; Allen JR; Baumann DD; Deitz SL; Blazek JD; Newbauer A; Darrah A; Long BC; Young B; Clement M; Doerge RW; Roper RJ Am J Med Genet A; 2013 Aug; 161A(8):1866-74. PubMed ID: 23843306 [TBL] [Abstract][Full Text] [Related]
15. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. Belichenko PV; Kleschevnikov AM; Masliah E; Wu C; Takimoto-Kimura R; Salehi A; Mobley WC J Comp Neurol; 2009 Feb; 512(4):453-66. PubMed ID: 19034952 [TBL] [Abstract][Full Text] [Related]
16. Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome. Marland JR; Smillie KJ; Cousin MA PLoS One; 2016; 11(1):e0147974. PubMed ID: 26808141 [TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033 [TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome. Gómez de Salazar M; Grau C; Ciruela F; Altafaj X Front Mol Neurosci; 2018; 11():226. PubMed ID: 30140203 [TBL] [Abstract][Full Text] [Related]
19. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Clark S; Schwalbe J; Stasko MR; Yarowsky PJ; Costa AC Exp Neurol; 2006 Jul; 200(1):256-61. PubMed ID: 16624293 [TBL] [Abstract][Full Text] [Related]